Semaglutide Background Technology
Diabetes mellitus is a group of lifelong metabolic diseases characterized by chronic hyperglycemia caused by multiple etiologies. According to the latest data from the International Diabetes Federation (IDF), the number of adults with diabetes worldwide has reached 425 million, of which type II diabetes accounts for 90%.
According to the statistics of the World Health Organization, there are more than 100 complications of diabetes, which is the disease with the most known complications. More than half of diabetes deaths are caused by cardiovascular and cerebrovascular diseases, and 10% are caused by nephropathy. Clinical data show that about 10 years after the onset of diabetes, at least 30% to 40% of patients will develop at least one complication, and once a complication occurs, it is difficult to reverse it with drug treatment. Therefore, early prevention of diabetic complications is emphasized.
At present, the commonly used hypoglycemic drugs mainly include insulin and its analogues, GLP-1 receptor agonists, DDP-4 enzyme inhibitors, metformin and other types. Among them, semaglutide, which was approved by the US FDA on December 6, 2017, has great advantages in the fields of hypoglycemia and weight loss.
At the same time, semaglutide is also the third hypoglycemic drug that has shown cardiovascular benefits after empagliflozin and liraglutide. Semaglutide is a GLP‑1 analogue with 94% homology to human GLP‑1.
Peptide Impurities & Peptide Characterization
Most peptide drugs are obtained by solid-phase synthesis techniques. Solid-phase synthesis begins with the first amino acid connected to the solid-phase carrier, and through a cyclic process of deprotection, activation, and condensation coupling, the amino acids are connected one by one until the target sequence peptide is obtained.
During the synthesis and storage of polypeptide drugs, it is easy to form related structural impurities, such as amino acid loss, amino acid insertion, protective group residue, oxidation/reduction, side chain modification, terminal modification, aggregates, etc. Many related structural impurities not only have no drug effect, but have certain toxic side effects in semaglutide Impurities.
During the drug development stage and clinical use, the analysis and control of peptide-related structural impurities is one of the important factors to be considered. It is very important to develop accurate analysis methods for the sequence and modification of impurities in peptide drugs. The development of tandem mass spectrometry and high-resolution mass spectrometry will play an important role in the field of impurity analysis in peptide drugs.
Omizzur lab customizes and synthesizes various peptide impurities, such as semaglutide impurities, exenatide impurities, etc for scientific research use. The delivery date within 2-4 weeks. we are renowned for our high cost-effectiveness. Omizzur will have the ability to assist you with your research projects. Please contact us to obtain the product details.